Journals / Türkiye Sağlık Enstitüleri Başkanlığı Dergisi / 2022 / Cilt: 5 - Sayı: 2

HMGCR GENE EXPRESSION IN DIFFERENT BREAST CANCER CELL LINES

Pages
12–19
Publication Date
2022-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The reason for this was thought to be related to the location of cancer formation or the age of the patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer is the one of the most common cancer types among women in the world.
📊
Key Findings & Data:In the first step of the pathway, 3-hydroxy-3-methylglutaryl coenzyme A, known as HMG-CoA, is converted to mevalonate by the rate-limiting enzyme HMGCR and the final product is farnesyl pyrophosphate called FPP, which is the building block of cholesterol.
💡
Conclusion & Impact:The reason for this was thought to be related to the location of cancer formation or the age of the patient.
🔬Design:Research Article
📍Scope:2080 Verileri
⚙️Variables:Breast cancer · HMGCR · Cholesterol metabolism

Özet

Breast cancer is the one of the most common cancer types among women in the world. Breast cells can be divided uncontrollably in either lobules or ducts. Breast cancer can be in situ or invasive, depending on its type. Cholesterol homeostasis is an important parameter for cancer progression. In normal cells, cholesterol is tightly regulated with de nova synthesis named as mevalonate pathway. In this pathway, important intermediates are produced for production of cholesterol. In the first step of the pathway, 3-hydroxy-3-methylglutaryl coenzyme A, known as HMG-CoA, is converted to mevalonate by the rate-limiting enzyme HMGCR and the final product is farnesyl pyrophosphate called FPP, which is the building block of cholesterol. In this study, we aimed to determine the expression levels of the HMGCR gene, which encodes 3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme, in different breast cancer cell lines: MDA-MB 231, MDA-MB 435, MDA-MB 453, UACC 2080, MCF-7, HCC 1938 via real-time PCR. As a result, we found that the MCF7 cell line has the lowest level of HMGCR mRNA, and the MDA-MB-453 cell line has the highest level of HMGCR mRNA. Differences in expression levels may be due to hormone receptors. Furthermore, other triple negative cell lines showed different expression levels among themselves, although they expressed more HMGCR than MCF-7. The reason for this was thought to be related to the location of cancer formation or the age of the patient.

🔖

Cite This Article

ŞENTÜRK, B., BAYRAK, A. M., YÜCEL, B. (2022). HMGCR GENE EXPRESSION IN DIFFERENT BREAST CANCER CELL LINES. Türkiye Sağlık Enstitüleri Başkanlığı Dergisi, Cilt: 5 - Sayı: 2, 12–19. https://ajindex.com/articles/843168

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Bjarnadottir, O., Feldt, M., Inasu, M., Bendahl, P., Elebro, K., Kimbung, S., & Borgquist, S. (2020).
  2. Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. Scientific Reports, 10(1). doi: 10.1038/s41598-019-57323-9
  3. Breast cancer. (2021). Retrieved 24 July 2022, from https://www.who.int/news-room/fact-sheets/detail/breast-cancer
  4. Burstein, H., Polyak, K., Wong, J., Lester, S., & Kaelin, C. (2004). Ductal Carcinoma in Situ of the Breast. New England Journal Of Medicine, 350(14), 1430-1441. doi: 10.1056/nejmra031301 Chimento A, Casaburi I, Avena P, Trotta F, De Luca A, Rago V, Pezzi V, Sirianni R. Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment. Front Endocrinol (Lausanne). 2019 Jan 21;9:807. doi: 10.3389/fendo.2018.00807. PMID: 30719023; PMCID: PMC6348274. Clendening, J., & Penn, L. (2012). Targeting tumor cell metabolism with statins. Oncogene, 31(48), 4967-4978. doi: 10.1038/onc.2012.6 Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15051-6. doi: 10.1073/pnas.0910258107. Epub 2010 Aug 9. PMID: 20696928; PMCID: PMC2930553. Creighton, C. (2012). The molecular profile of luminal B breast cancer. Biologics: Targets And Therapy, 289. doi: 10.2147/btt.s29923 Danilo, C., & Frank, P. (2012). Cholesterol and breast cancer development. Current Opinion In Pharmacology, 12(6), 677-682. doi: 10.1016/j.coph.2012.07.009 Demircan, B., Yucel, B., & Radosevich, J. (2019). DNA Methylation in Human Breast Cancer Cell Lines Adapted to High Nitric Oxide. In Vivo, 34(1), 169-176. doi: 10.21873/invivo.11758 Desai, S., Moonim, M., Gill, A., Punia, R., Naresh, K., & Chinoy, R. (2000). Hormone receptor status of breast cancer in India: a study of 798 tumours. The Breast, 9(5), 267-270. doi: 10.1054/brst.2000.0134 Ding, X., Zhang, W., Li, S., & Yang, H. (2019). The role of cholesterol metabolism in cancer. American journal of cancer research, 9(2), 219–227.
  5. Frykberg ER, Bland KI. In situ breast carcinoma. Advances in Surgery. 1993;26:29-72. PMID: 8380307. Goldstein, J., & Brown, M. (1990). Regulation of the mevalonate pathway. Nature, 343(6257), 425-430. doi: 10.1038/343425a0 Göbel, A., Breining, D., Rauner, M., Hofbauer, L., & Rachner, T. (2019). Induction of 3-hydroxy-3-methylglutaryl-CoA reductase m